Maeda Y, Takemura T, Chikata T, Kuwata T, Terasawa H, Fujimoto R
J Virol. 2020; 94(12).
PMID: 32295903
PMC: 7307085.
DOI: 10.1128/JVI.00193-20.
Silver Z, Dickinson G, Seaman M, Desrosiers R
J Virol. 2019; 93(10).
PMID: 30842322
PMC: 6498048.
DOI: 10.1128/JVI.00094-19.
C Antell G, Dampier W, Aiamkitsumrit B, Nonnemacher M, Jacobson J, Pirrone V
Retrovirology. 2016; 13(1):32.
PMID: 27143130
PMC: 4855882.
DOI: 10.1186/s12977-016-0266-9.
Cashin K, Sterjovski J, Harvey K, Ramsland P, Churchill M, Gorry P
PLoS One. 2014; 9(10):e109771.
PMID: 25313689
PMC: 4196930.
DOI: 10.1371/journal.pone.0109771.
Brandenberg O, Rusert P, Magnus C, Weber J, Boni J, Gunthard H
Retrovirology. 2014; 11:75.
PMID: 25287422
PMC: 4190450.
DOI: 10.1186/s12977-014-0075-y.
Bioinformatic analysis of HIV-1 entry and pathogenesis.
Aiamkitsumrit B, Dampier W, Antell G, Rivera N, Martin-Garcia J, Pirrone V
Curr HIV Res. 2014; 12(2):132-61.
PMID: 24862329
PMC: 4382797.
DOI: 10.2174/1570162x12666140526121746.
Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques.
Ren W, Mumbauer A, Zhuang K, Harbison C, Knight H, Westmoreland S
Retrovirology. 2013; 10:9.
PMID: 23369442
PMC: 3571932.
DOI: 10.1186/1742-4690-10-9.
Genotypic prediction of HIV-1 subtype D tropism.
Raymond S, Delobel P, Chaix M, Cazabat M, Encinas S, Bruel P
Retrovirology. 2011; 8:56.
PMID: 21752271
PMC: 3146927.
DOI: 10.1186/1742-4690-8-56.
Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.
Dimonte S, Mercurio F, Svicher V, DArrigo R, Perno C, Ceccherini-Silberstein F
Retrovirology. 2011; 8:33.
PMID: 21569409
PMC: 3117778.
DOI: 10.1186/1742-4690-8-33.
Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.
Ringe R, Thakar M, Bhattacharya J
Retrovirology. 2010; 7:76.
PMID: 20860805
PMC: 2955667.
DOI: 10.1186/1742-4690-7-76.
Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.
Del Prete G, Leslie G, Haggarty B, Jordan A, Romano J, Hoxie J
J Virol. 2010; 84(17):8777-89.
PMID: 20573813
PMC: 2919036.
DOI: 10.1128/JVI.00333-10.
R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch.
Tasca S, Ho S, Cheng-Mayer C
J Virol. 2008; 82(14):7089-99.
PMID: 18480460
PMC: 2446975.
DOI: 10.1128/JVI.00570-08.
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies.
Delobel P, Nugeyre M, Cazabat M, Pasquier C, Marchou B, Massip P
J Clin Microbiol. 2007; 45(5):1572-80.
PMID: 17329448
PMC: 1865905.
DOI: 10.1128/JCM.02090-06.
Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.
Kiselyeva Y, Nedellec R, Ramos A, Pastore C, Margolis L, Mosier D
J Virol. 2007; 81(7):3657-61.
PMID: 17202224
PMC: 1866070.
DOI: 10.1128/JVI.02310-06.
Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.
Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell J, Derdeyn C
J Virol. 2006; 81(3):1350-9.
PMID: 17079307
PMC: 1797511.
DOI: 10.1128/JVI.01839-06.
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier D
J Virol. 2005; 80(2):750-8.
PMID: 16378977
PMC: 1346864.
DOI: 10.1128/JVI.80.2.750-758.2006.
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Kuhmann S, Pugach P, Kunstman K, Taylor J, Stanfield R, Snyder A
J Virol. 2004; 78(6):2790-807.
PMID: 14990699
PMC: 353740.
DOI: 10.1128/jvi.78.6.2790-2807.2004.
Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.
Nabatov A, Pollakis G, Linnemann T, Kliphius A, Chalaby M, Paxton W
J Virol. 2003; 78(1):524-30.
PMID: 14671134
PMC: 303404.
DOI: 10.1128/jvi.78.1.524-530.2004.
A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick M, Kelleher R, Jensen R, Labrijn A, Wang M, Quinnan Jr G
J Virol. 2003; 77(12):6965-78.
PMID: 12768015
PMC: 156200.
DOI: 10.1128/jvi.77.12.6965-6978.2003.
Target cell populations of human immunodeficiency virus type 1 in peripheral blood lymphocytes with different chemokine receptors at various stages of disease progression.
Auewarakul P, Sangsiriwut K, Suwanagool S, Wasi C
J Virol. 2001; 75(14):6384-91.
PMID: 11413305
PMC: 114361.
DOI: 10.1128/JVI.75.14.6384-6391.2001.